Kkr Real Estate Finance Trust Stock Earnings Reports

KKR Real Estate Finance Trust (KREF) frames 2026 as a transition year focused on cleaning up legacy and watch-list assets, reducing REO footprint, and repositioning the portfolio into newer-vintage, higher-quality loans. Q1 results: GAAP net loss of $62M (−$0.96/sh), book value $11.87/sh (down 9% QoQ), distributable loss $4M (−$0.06/sh), distributable earnings before realized losses $13M ($0.20/sh). Management prioritized two main objectives: (1) an aggressive resolution strategy for watch-list loans and legacy office exposures (targeting legacy office exposure below 10% from 21%), and (2) converting portions of REO to liquidity and redeploying capital into newer originations. They expect loans originated 2024–2026 to represent ~50% of the portfolio by year-end. Capital/cash: $653M total liquidity at quarter-end (including $135M cash and $500M undrawn revolver capacity), $2B+ of expected repayments in 2026, total financing availability $7.2B, and leverage within target ranges (debt-to-equity 2.2x, total leverage ~4x). Management reduced the quarterly dividend to $0.10 (payable July 15) to preserve capital optionality and pursue share repurchases; Board authorized a $75M buyback program. They recorded CECL provisions of $74M this quarter (total allowance $260M) and expect to resolve all watch-list loans by year-end. Key REO actions: segregated near/medium/long-term monetization buckets with specific assets highlighted (West Hollywood condos; Raleigh multifamily; Philadelphia office—to be sold; Mountain View office—signed long-term lease with OpenAI and expected to market in 12–16 months; Portland redevelopment—monetization underway; Seattle and Boston life science—longer holds). Management anticipates transaction-driven near-term pressure on earnings (earnings expected to trough H2 2026 into H1 2027) but sees a path to rebuild earnings and book value through REO monetization, new originations, and buybacks. Guidance/other: expect to cover the new $0.40 annual dividend by earnings excluding realized losses over time, quarterly variability likely; one additional life-science loan likely to go to REO; management evaluating capital structure and fee/support options with KKR on the table.